H.U. Group Holdings, Inc.
H.U. Group Holdings’ 2026 Financial Results | Revenue of ¥2,473.3 billion, Net Income of ¥6.8 billion
H.U. Group's consolidated financial results for the fiscal year ending March 2026 show revenue of ¥2,473.362 billion (an increase of 1.8%) and net income attributable to shareholders of ¥6.823 billion (a rise of 147.1%). Segments such as testing and related services performed steadily, with operating profit expanding to ¥4.78 billion. The planned dividend for the period is ¥125 per share.
Key Figures
- Revenue: ¥2,473.362 billion (up 1.8% YoY)
- Net income attributable to shareholders: ¥6.823 billion (up 147.1% YoY)
- Dividend: ¥125 (annual estimate)
AI要約
Performance Overview
H.U. Group achieved revenue of ¥2,473.362 billion (an increase of 1.8%), operating profit of ¥4.78 billion (an increase of 81.0%), and net income attributable to shareholders of ¥6.823 billion (an increase of 147.1%) for the fiscal year ending March 2026. Steady performance was observed in testing and related services segments and clinical diagnostic reagent businesses, especially driven by new blood testing products and FDA approvals in the United States. The planned dividend for the year is ¥125 per share, with continual share buyback programs in place. Overall, the company maintains profitability and financial soundness while anticipating future growth.
Outlook and Shareholder Impact
For the fiscal year ending March 2027, the company anticipates revenue of ¥2,560.0 billion (a 3.5% increase) and net income of ¥5.0 billion (a 26.7% decrease). The dividend remains at ¥125 per share, with ongoing share buyback initiatives. The company intends to sustain a solid financial position with a capital adequacy ratio of 51.3%, promoting growth strategies accordingly.
Revenue Trend
Operating Profit Trend
Segment Revenue Breakdown
Profit Margin Analysis
2027 Forecast vs. Actual Comparison
H.U. Group Holdings, Inc.
Company overview · Stock price · Financial data · All IR
